Clinical trials: Ophthalmic Solutions
Healthy Cornea
Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution Administration
The goal of this clinical trial is to evaluate the corneal endothelium health of eyes treated with articaine ophthalmic solution in adult participants.
- Trial name
- NCT07838129
- Testing
- Articaine (CYKLX), Vehicle
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Laboratoires Thea
Dry Eye Syndrome
Study of TOP1630 for Dry Eye Syndrome
In subjects with Dry Eye Syndrome (DES): The primary objective of this study is to confirm the efficacy of TOP1630 0.1% Ophthalmic Solution TID OU compared to placebo treatment at Day 29 on pre-specified sign and symptom…
- Trial name
- THEIA-1 (NCT03833388)
- Testing
- TOP1630 0.1% Ophthalmic Solution TID OU
- Where
- 4 sites in United States
- Volunteers
- 202 people
- Sponsor
- Topivert Pharma Ltd
Antiseptic, Anesthesia, Local
The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine
To evaluate if Iheezo's (chloroprocaine 3%) gel vehicle acts as a barrier on the ocular surface, potentially blocking the bactericidal action of povidone-iodine.
- Trial name
- NCT05934253
- Testing
- Chloroprocaine ophthalmic gel 3%
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harrow Inc
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Assess the Patient Feeling About the Handiness of Two Different Vials Used to Deliver Both, Unpreserved Hyaluronic Eye Drops
Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials
Assess the patient feeling about the handiness of two different vials used to deliver both, unpreserved hyaluronic eye drops.
- Trial name
- NCT01546012
- Testing
- HYABAK®, HYLO-COMOD®
- Where
- Germany
- Sponsor
- Laboratoires Thea
Cataracts
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain…
- Trial name
- NCT00405730
- Testing
- Nepafenac 1mg/ml eye drops, suspension, Ketorolac Trometamol 5 mg/ml eye drops, solution, Nepafenac vehicle eye drops
- Where
- France
- Volunteers
- 227 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Dry Eye Syndromes
Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye
The primary objective of this study is to evaluate the efficacy of REMOGEN® OMEGA in reducing Dry Eye Syndrome (DES) symptoms.
- Trial name
- REMOTOP (NCT02908282)
- Testing
- REMOGEN OMEGA, Povidone
- Where
- 5 sites in Germany
- Volunteers
- 81 people
- Sponsor
- TRB Chemedica AG
Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery
A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
This study is designed to assess whether an investigational eye drop called CA201A can help protect the cornea (the outer covering of the eye) and reduce damage to corneal endothelial cells following cataract surgery, without…
- Trial name
- NCT07694375
- Testing
- Ophthalmic solution (matching formulation without ascorbic acid), Ascorbic acid ophthalmic solution 5%
- Where
- 8 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Caravel Oculus Pty Ltd
Macular Degeneration, Diabetic Retinopathy
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible…
- Trial name
- NCT00414999
- Testing
- TG100801
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- TargeGen
Cataract Surgery
Efficacy and Safety of Bromfenac Ophthalmic Solution
This is a safety and efficacy study of bromfenac ophthalmic solution
- Trial name
- NCT00585975
- Testing
- bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
- Trial name
- NCT01561521
- Testing
- AKF-1
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Akorn, Inc.
Adenoviral Conjunctivitis
Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the…
- Trial name
- Goldeneye (NCT03009799)
- Testing
- Iota-Carrageenan, Carmellose
- Where
- Spain
- Sponsor
- NicOx
Cataract
Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops
The purpose of the study is to confirm that Vigamox reaches similar aqueous concentration when administered as the commercially available eye drops or as a spray delivered from a proprietary device.
- Trial name
- NCT00565630
- Testing
- Vigamox delivered via the device in spray form
- Volunteers
- 16 people
- Sponsor
- Advanced Ophthalmic Pharma
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Glaucoma
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07168902
- Testing
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- Bausch & Lomb Incorporated
Erythematous Rosacea
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
- Trial name
- NCT00697541
- Testing
- 0.18% COL-118 facial gel (1.8 mg brimonidine), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop), Advanced Eye Relief
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Dry Eye Disease
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
- Trial name
- NCT05403827
- Testing
- K-161
- Where
- 51 sites in United States
- Volunteers
- 644 people
- Sponsor
- Kowa Research Institute, Inc.
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Corneal Epithelium Defect
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops
A multicenter, randomized, double-blind, placebo-controlled clinical trial was designed. A total of 120 subjects were randomly assigned to two experimental groups (lowe-dose ZKY001 eye drops group,Medium-dose ZKY001 eye drops…
- Trial name
- TPRK (NCT06209203)
- Testing
- lowe-dose ZKY001 eye drops, Medium-dose ZKY001 eye drops
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.